Clinical trial
Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine…
NCT00324051 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00324051 |
|---|---|
| Title | Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet |
| Official title | PREFERENCE: 12-Week Open Label Trial On Olanzapine Orodispersible Tablet Vs. Oral Olanzapine Preference Study |
| Acronym | PREFERENCE |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | olanzapine therapy |
| Enrollment | 284 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | May 10, 2006 |
| Last update posted | Sep 12, 2019 |
| Countries | Brazil, Romania, Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: